Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gauzy To Contact Him Directly To Discuss Their Options

VanEck Rare Earth and Strategic Metals ETF earns a Buy rating as a portfolio diversifier targeting rare earth element exposure. REMX offers concentrated, liquid exposure to 26 REE-related equities, balancing regional allocations across Australia, China, and the US. Secular demand for REEs outside China, supply chain concerns, and strategic investments—such as in MP Materials—support the investment thesis.

NioCorp Developments is a pre-revenue, US-based miner focused on niobium, scandium, and titanium, rated a Strong Buy after a significant pullback. NB's Elk Creek project is fully permitted, with a 38-year mine life, projected $21.9B gross revenue, and 68% EBITDA margin; production start is 3–4 years away. Current EV of $521M implies a forward EV/EBITDA of 1.29, presenting substantial upside versus sector median multiples, even without rare earth expansion.

A $10,000 Verizon investment in 2015 would be worth just $14,650 today, badly trailing the S&P 500. The same investment made in 2005 grew to $27,400 by 2015, beating the market.

Uber leads the global rideshare and delivery markets. Uber continues to grow its revenue and profits.

Jack in the Box is closing dozens of restaurants as part of a major cost-cutting plan, with 72 locations shuttered so far and more expected in the near future.

Enbridge operates in the most stable segment of the energy sector. The company's reliable cash flows support its attractive yield of 5.9%.

Nvidia licensed Groq's AI inference technology and hired key engineers. Groq will continue to operate independently after the non-exclusive licensing agreement.

Italian regulators ordered Meta on Wednesday to open its WhatsApp chat platform to rival AI chatbots as it and EU authorities pursue a probe that the US tech giant is abusing its dominant market position.

According to the European Automobile Manufacturers' Association (ACEA) November report on EU car registrations, the figure for Tesla Inc.

BYD's registrations in the European Union were up 235.2% in November to 16,158, according to the European Automobile Manufacturers' Association (ACEA).

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a condition affecting millions worldwide with limited effective treatment options.

Intel Corp (NASDAQ:INTC, XETRA:INL) shares fell on Wednesday on a Reuters report that Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) had halted a test of Intel's advanced 18A chipmaking process. According to Reuters, which cited two people familiar with the matter, Nvidia had been evaluating whether its chips could be manufactured using Intel's 18A process, one of Intel's most advanced production technologies.

TTM Technologies (TTMI) is a critical supplier to the AI hardware and defense sectors, with 22% y/y sales growth and record earnings. TTMI's growth is driven by surging AI data center demand and robust aerospace & defense spending, with 80% of Q3 sales tied to these arenas. Despite a 189% YTD stock surge, TTMI trades at a discount on PEG and price/sales metrics relative to sector growth, justifying a Strong Buy rating.

The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.

FS KKR Capital is cutting its base cash dividend by 29.7% to $0.45 per share, with the BDC's yield now the largest versus its large-cap peers. The move comes as NAV per share grew marginally during the third quarter by 6 cents sequentially, against what's been a broader decline since 2023. FSK is trading at a material 34% discount to NAV, with the move to reduce its dividend set to be helpful to drive a recovery and a possible discount narrowing.

JPM is weighing crypto trading for institutions as regulation eases, signaling a shift that could add liquidity and intensify competition.

Some may doubt the Santa Rally this year amid AI overvaluation and inflation woes. Low P/E momentum ETFs -- XMVM, XSVM, PYZ, VAMO -- offer a balanced year-end play.

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic breast cancer in pivotal phase 3 trials. Company's palazestrant + KISQALI combination achieved a promising 15.5-month mPFS in heavily pretreated patients, addressing endocrine resistance in both ESR1-mutant and wild-type tumors. Key catalysts include OPERA-01 monotherapy data expected in 2H 2026 and OPERA-02 topline results in 2028, with potential NDA filing in 2027 for monotherapy if successful.

Transaction in Own Shares 24 December, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 24 December, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 24/12/2025 358,799 27.1400 27.0150 27.0785 LSE GBP 24/12/2025 - - - - Chi-X (CXE) GBP 24/12/2025 - - - - BATS (BXE) GBP 24/12/2025 309,528 31.1650 31.0100 …